26/05/2014 GP/EFSA/AHAW/2012/01: Echinococcus multilocularis infection in animals To prepare for the future opinion (EU regulation 1152/2011): GP/EFSA/AHAW/2012/01: Echinococcus multilocularis infection in animals THE AIM: • Identify and collate the current knowledge and data on 9 Epidemiological points; • Apply systematic reviews of literature and data. HERACLES Adriano Casulli European Reference Laboratory for Parasites Istituto Superiore di Sanità (Rome, Italy) 1 26/05/2014 H.E.R.A.C.L.E.S. The EC launched a SPECIFIC CALL (First Time!!) on neglected infectious diseases. Human cystic Echinoccosis ReseArch in CentraL and Eastern Societies • THEME: HEALTH.2013.2.3.4-1: Neglected infectious diseases of Central and Eastern Europe • FUNDING SCHEME: Collaborative Project. • THE AIM: establish an integrated approach for the development of preventive, therapeutic and diagnostic tools for NID. This action support innovative, collaborative biomedical research proposals. Focus on one or more viral, bacterial, protozoan, and/or helminthic human diseases. P LEGAL NAME ACRONYM TYPE COUNTRY Principal Investigator 1 ISTITUTO SUPERIORE di SANITÀ ISS Research Institute ITALY DR. ADRIANO CASULLI 2 UNIVERSITÀ di PAVIA UNIPV University Hospital ITALY Dr. Enrico Brunetti 3 AGENCIA ESTATAL CONSEJO SUPERIOR de INVESTIGACIONES CIENTÍFICAS CSIC Research Institute SPAIN Dr. Maria del Mar Siles‐Lucas 4 SPITALUL CLINIC COLENTINA BUCURESTI CCHUMFCD University Hospital ROMANIA Prof. Carmen Michaela Cretu 5 HACETTEPE UNIVERSITESI HUSMDR University Hospital TURKEY Prof. Okan Akhan 6 HOSPITAL for ACTIVE TREATMENT of INFECTIOUS and PARASITIC DISEASES "PROF. I. KIROV” SHATIPD University Hospital BULGARIA Prof. Kamena Vutova 10 NAMIK KEMAL UNIVERSITESI NKU University TURKEY Prof. Gulay Vural 8 ALTA Ricerca e Sviluppo in Biotecnologie S.R.L.U. ALTA Service provider company ITALY Dr. Aldo Tagliabue 9 VIRCELL S.L. VIRCELL S.M.E. SPAIN Dr. Arantxa Cortes Ruiz Timing: 1st October, 2013 - 2017 2 26/05/2014 Consortium and Centres involved in the “Extended Family” Countries of origin of the Consortium HERACLES governance WP4 CE ultrasound screening WP1 Enantiomeric drug development WP5 ERCE registry WP6 Management and IPR Training and dissemination Host-parasite interplay EchinoBioBank WP3 WP2 New molecular based tools 3 26/05/2014 Themain mainGOALS GOALSof ofHERACLES HERACLESare: are: The The main GOALS of HERACLES are: • Identify the EEC population affected by CE by ultrasound screening; • Set-up and validate new molecular-based PoC-LoC immunological surveillance, rapid diagnosis and follow-up; kits for • Create the European Registry of Cystic Echinococcosis (ERCE) for the surveillance of CE to provide baseline data for risk calculations and to establish a prospective case retrieval; • Establish the Echino-Bio-Bank from animal and human CE patients and related Databases; • Identify the molecular bases associated with CE response to therapy or lack thereof, through the of host-parasite interplay (omic studies); HUMAN IMMUNITY PARASITE VIRULENCE CLINICAL RECORDS The main GOALS of HERACLES are: ERCE REGISTRY • Increase drug bioavailability of ABZ in an in vivo model and to synthesize a new enantiomeric drug based on ABZ; O CE ULTRASOUND SCREENING O H N S * HOSPITAL NETWORK O N H N (+)-(R)-ABZ-SO O S * HUMAN SAMPLES COLLECTION O H N O N H N (-)-(S)-ABZ-SO • Train people working in EEC, as they are crucial to fight this disease. Dissemination: EU citizens; experts; public health authorities; policy makers. Training: staff exchange; ultrasound on CE, PAIR and related techniques; Laboratory techniques; educational events. ANIMAL SAMPLES COLLECTION ECHINO-BIO-BANK IN VIVO ANIMAL MODEL VALIDATION of MOLECULAR TOOLS ABZ BIOAVAILABILITY and ENANTIOMERIC DRUG SYNTHESIS COMMERCIAL POC-LOC KIT HOST-PARASITE INTERPLAY 4 26/05/2014 More info: http://www.Heracles-fp7.eu/ ......is growing! Any lessons learned are likely to be applicable and useful for other countries, especially in the underserved areas, where CE represents an important health problem. 5
© Copyright 2024 ExpyDoc
